Assessment of patients undergoing therapeutic plasmapheresis

Abstract

AimTherapeutic plasma exchange (TPE) is an extracorporeal treatment technique that allows the removal of unwanted substances with large molecule weight from the blood. In this study, it was aimed to retrospectively assess patients who underwent therapeutic plasmapheresis.MethodsThe medical data of patients who underwent TPE in the 10-bed pediatric intensive care unit of Ümraniye TRH between May 2017 and May 2018 were retrospectively assessed. Age, sex, body weight, plasmapheresis indications, plasmapheresis technique, complication and mortality rates were recorded.ResultsTPE was performed in a total of 19 patients. The mean age of the study population was 8.8 ± 5.9 years. Ten (52.6%) patients were provided respiratory support with mechanical ventilator; the mean duration of ventilator support for these patients was 10.3 ± 10 days. The most common indication for TPE was autoimmune encephalitis with a rate of 42% (8/19 patients); the other indications were collagen tissue disorder activation, hepatic failure, mitochondriopathic encephalopathy, Guillain-Barre syndrome, septic shock, and hemophagocytic syndrome. The patients were administered a total of 5.94 ± 1.69 sessions of TPE (min 3-max 8). As a replacement fluid, fresh frozen plasma (FFP) was used in 17 patients and albumin in 2 patients. The most common complication was catheter-related complications. None of the patients died during the procedure. One patient followed for Hashimoto encephalitis and another patient followed for septic shock died.ConclusionTPE is an invasive treatment method but with a low side-effect profile; it is used to stop disease progression in life-threatening autoimmune disorders unresponsive to medical treatment.

Keywords

Additional Information

Publisher’s Note
Bayrakol MP remains neutral with regard to jurisdictional and institutional claims.

Rights and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0). To view a copy of the license, visit https://creativecommons.org/licenses/by-nc/4.0/

View full license details →